Keith Lenden

Keith Lenden is a seasoned biotechnology and pharmaceutical professional with extensive experience in venture capital and drug development. Currently serving as a Venture Partner at ARCH Venture Partners since June 2017, Lenden co-founded several companies, including Autobahn Therapeutics, Inc. and Boundless Bio, focusing on CNS drug discovery and ecDNA oncology research, respectively. Previously, Lenden co-founded Abide Therapeutics and Receptos, both of which were successfully acquired by larger firms. Lenden held leadership roles at Esperion Therapeutics, Maxygen, Acologix, and Genteric, and began a career in consultancy at LEK Consulting. Lenden's academic credentials include an MBA from the University of California, Berkeley, and engineering degrees from Dartmouth College. Lenden is also a recognized Kauffman Fellow.